Is Low-Dose Testosterone Safe While Trying to Conceive?

The Short Answer: Testosterone and Trying to Conceive Do Not Mix

Low-dose testosterone should not be used while you are trying to get pregnant. Full stop. Testosterone crosses the placenta. Exposure of a female fetus to excess androgens causes virilization, a pattern of irreversible masculinization of external genitalia that has been documented in the medical literature for decades. Male fetuses may also be affected by supraphysiologic androgen exposure, though the female fetal risk is the better-characterized concern.

The FDA prescribing information for testosterone products states explicitly that testosterone is contraindicated during pregnancy. This applies to all formulations, including the low-dose compounded transdermal preparations commonly prescribed off-label to women for HSDD or low libido.

If you are currently taking compounded transdermal testosterone and are now trying to conceive or have just discovered you are pregnant, contact your prescribing clinician today. Do not wait for your next scheduled visit.

What Low-Dose Testosterone Is Actually Prescribed For in Women

Low-dose testosterone is not FDA-approved for any indication in women in the United States. Every prescription a woman receives is off-label, and the most common reasons clinicians prescribe it are:

• Hypoactive sexual desire disorder (HSDD), particularly in postmenopausal women
• Low libido associated with surgical menopause or oophorectomy
• Off-label use in perimenopausal women with fatigue or low mood alongside low androgens
• Occasionally, androgen add-back in women on GnRH agonist therapy for endometriosis

What the Evidence Actually Supports

The strongest evidence base for low-dose testosterone in women comes from postmenopausal populations. The ISSWSH (International Society for the Study of Women's Sexual Health) 2019 Process of Care consensus concluded that testosterone therapy may benefit postmenopausal women with HSDD, but explicitly noted that data in premenopausal women are limited and insufficient to support routine use.

A 2019 systematic review and meta-analysis published in The Lancet Diabetes and Endocrinology covering 36 randomized trials found that testosterone improved sexual function scores in postmenopausal women. The authors noted that premenopausal women were substantially underrepresented across those trials, and that safety data for women of reproductive age using testosterone are sparse.

Doses Used in Women

Typical doses in women's health practice run from 300 micrograms to 1.5 milligrams per day transdermal, aiming to restore serum testosterone to the upper end of the normal premenopausal female range (roughly 15 to 70 ng/dL). These doses are dramatically lower than those used in male hormone therapy. Even so, they are not safe during pregnancy.

Why Testosterone Is Dangerous During Pregnancy

The Mechanism: Virilization of Female Fetuses

Testosterone and other androgens freely cross the human placenta. When a female fetus is exposed to supraphysiologic androgens during the critical window of genital differentiation, typically between weeks 7 and 12 of gestation, the external genitalia can develop along a masculinized pattern. This includes clitoral enlargement, labial fusion, and ambiguous genitalia, a presentation grouped under the term disorders of sex development (DSD) or congenital adrenal hyperplasia-like phenotype.

A 2020 review in the Journal of Clinical Endocrinology and Metabolism confirmed that androgen exposure at any point in fetal development carries risk, with the first trimester representing the highest-risk window for external genitalia virilization and later exposure potentially affecting other androgen-sensitive tissues.

Human Evidence: Case Reports and Observational Data

No randomized controlled trial has ever studied intentional testosterone use during human pregnancy, for obvious ethical reasons. What exists is a body of case reports and observational data.

Women with conditions that raise endogenous androgens during pregnancy, including congenital adrenal hyperplasia, androgen-secreting ovarian tumors, and luteomas of pregnancy, provide indirect human evidence. A case series published in AJOG documented virilization of female offspring in pregnancies complicated by maternal androgen excess, confirming that the placental transfer seen in animal models also occurs in humans.

The case reports of iatrogenic exposure (women who unknowingly continued testosterone therapy into early pregnancy) consistently report the same pattern: female fetuses are the ones most visibly affected, with male fetuses showing less obvious phenotypic change because their endogenous androgen production already drives similar developmental signals.

Animal Data

Animal studies are unambiguous. FDA reproductive toxicology summaries for testosterone products note that administration of testosterone to pregnant rodents and rabbits causes fetal virilization and fetal death at doses that produce plasma levels within or near the human therapeutic range. These findings are why testosterone carries a formal contraindication in pregnancy, not merely a warning.

Is There a "Safe" Low Dose in Pregnancy?

No. There is no established safe dose of exogenous testosterone during pregnancy. The concept of a therapeutic window below which fetal harm does not occur has not been demonstrated in any controlled human study. The Endocrine Society's clinical practice guideline on androgen therapy in women does not describe any dose as safe in pregnancy and recommends against use.

A practical framework for women on testosterone who want to conceive:

| Step | Timing | Action | |------|---------|--------| | 1. Discuss discontinuation | At least 1 full menstrual cycle before TTC | Stop testosterone with prescriber guidance | | 2. Confirm serum testosterone | 4 to 6 weeks after stopping | Verify levels have returned toward baseline | | 3. Rule out early pregnancy before restarting | Any future restart | Pregnancy test required | | 4. Use contraception if remaining on testosterone | While sexually active | Non-hormonal or progestin-only methods depending on context |

There is no trial-validated washout period. The recommendation to stop at least one full cycle before attempting conception is a conservative clinical default based on the drug's half-life and the need to confirm ovulation and cycle regularity, not a formally studied interval.

Testosterone While Breastfeeding: Also Not Recommended

What LactMed Says

The National Institutes of Health LactMed database, the primary reference used by U.S. Clinicians for lactation drug safety, documents that testosterone transfers into human breast milk. The entry notes that testosterone and other androgens can suppress lactation, as androgens inhibit prolactin-mediated milk production. LactMed advises that testosterone is generally considered incompatible with breastfeeding.

The Suppression Problem

Even at low doses used in women's health, there is a plausible pharmacological mechanism for milk suppression. Androgens act directly on breast tissue to counter estrogenic and prolactin-driven lactation signaling. A review in Breastfeeding Medicine noted that women who receive androgenic compounds in the postpartum period show reduced milk volume compared with controls, though this was studied in the context of older, higher-dose androgen preparations rather than modern low-dose female regimens specifically.

What This Means for Postpartum Women

If you are postpartum, breastfeeding, and being considered for low-dose testosterone for HSDD or low libido (a real clinical scenario in the postpartum period, when androgen levels drop sharply after placental delivery), the safest approach at this time is to avoid testosterone until you have fully weaned. The evidence gap here is real. Dedicated lactation pharmacokinetic studies for low-dose compounded transdermal testosterone in postpartum women simply do not exist, and clinicians are extrapolating from older data on higher-dose preparations and from general androgen pharmacology.

This is one area where the evidence gap described in rule W6 is especially important to name plainly. The data we have are indirect. No one has measured transdermal testosterone transfer into milk in a study designed specifically around the 300-to-1500 microgram doses used in women's health practice today.

How This Differs Across Reproductive Life Stages

Reproductive Years (Not Trying to Conceive)

If you are of reproductive age, sexually active, not trying to conceive, and a clinician is considering low-dose testosterone for HSDD or androgen insufficiency, contraception is a required component of the plan. Non-hormonal methods (copper IUD, condoms) or progestin-only methods that do not add additional androgen activity are generally preferred. Combined hormonal contraceptives containing androgenic progestins may interact with the clinical picture and should be discussed carefully.

The ACOG Committee Opinion on Testosterone Therapy in Women notes that off-label testosterone use in premenopausal women requires careful risk-benefit assessment and that contraception is a prerequisite for sexually active women of reproductive age.

Perimenopause

Perimenopausal women represent a gray zone. Cycles may be irregular, making pregnancy detection unreliable. Any perimenopausal woman on testosterone who has not had 12 consecutive months of amenorrhea (the standard definition of menopause) should still use contraception and should not assume she cannot conceive. ACOG Practice Bulletin 141 on management of menopausal symptoms confirms that ovulation can occur unpredictably in perimenopause even with irregular cycles.

Postmenopause

Postmenopausal women (12-plus months of amenorrhea) are the population for whom the evidence on low-dose testosterone is strongest and for whom the conception risk is effectively absent. This is why the ISSWSH and The Menopause Society have focused their guidance primarily on this group.

The Menopause Society (formerly NAMS) 2022 Position Statement on Hormone Therapy does not endorse routine testosterone therapy for menopausal women but acknowledges the ISSWSH guidance on HSDD and notes that clinicians may consider it after a careful benefit-risk discussion. Pregnancy is not a concern in confirmed postmenopause.

Trying to Conceive (The Focus of This Article)

This is the clearest situation: stop testosterone before attempting conception. The drug offers no fertility benefit. No data support its use during ovulation induction, IVF cycles, or natural conception attempts. If you are working with a reproductive endocrinologist and testosterone was previously on your medication list, your RE should be informed, as androgen levels can affect follicular development and the hormonal milieu of early implantation.

Research published in Fertility and Sterility has examined androgen priming before IVF, but this refers to short-course, carefully dosed DHEA or testosterone protocols administered under close monitoring in specific poor-responder populations, not to ongoing low-dose testosterone use for HSDD. These are entirely different clinical scenarios and should not be conflated.

PCOS and Testosterone: A Special Caution

Women with polycystic ovary syndrome already have elevated androgens. PCOS is the most common endocrine disorder in reproductive-age women, affecting approximately 8 to 13 percent of women of reproductive age globally. Adding exogenous testosterone to a woman with PCOS who is trying to conceive would compound an existing androgen excess and is not indicated.

If you have PCOS and are experiencing low libido, the primary driver is rarely low testosterone. Addressing metabolic health, treating insulin resistance, and, if appropriate, using medications targeted at PCOS management are the correct first steps. Low-dose testosterone is not an appropriate PCOS treatment and carries added fetal risk in a group of women who may have irregular cycles and unexpected pregnancies.

Alternatives for Sexual Dysfunction in Women Who Want to Conceive

If low libido or sexual dysfunction is the reason you were prescribed testosterone, you deserve a clear picture of what alternatives exist, especially if you are trying to conceive or pregnant.

Non-Pharmacological Options

Cognitive behavioral therapy and mindfulness-based interventions for HSDD have the strongest evidence base for premenopausal women and carry no teratogenic risk. Sex therapy, pelvic floor physical therapy (particularly relevant in the postpartum period), and couples-based interventions all have data supporting improvement in sexual desire and satisfaction without pharmacological exposure.

Flibanserin (Addyi)

Flibanserin is the only FDA-approved medication for HSDD, and it is approved specifically for premenopausal women. It is contraindicated with alcohol and with strong CYP3A4 inhibitors, and its pregnancy safety has not been established. It should not be used during pregnancy or while trying to conceive without explicit clinician guidance.

Addressing Root Causes

Low libido in reproductive-age women is frequently driven by thyroid dysfunction, iron deficiency, depression, relationship factors, or the hormonal shifts of perimenopause and postpartum recovery. A thorough workup before prescribing any pharmacological agent is the appropriate clinical standard.

ACOG's guidance on sexual dysfunction in women emphasizes that a biopsychosocial assessment should precede any prescription, including hormone-based treatments.

What to Tell Your Clinician

If you are currently taking low-dose compounded testosterone and planning to conceive, bring these specific points to your next appointment:

1. Ask your prescriber to document the stop date in your chart and confirm when your serum testosterone levels should be rechecked.
2. Request a pregnancy test before any consideration of restarting testosterone after a pregnancy or breastfeeding period.
3. If you conceived while on testosterone (it happens, especially in perimenopause), tell your OB immediately. The timing of exposure relative to the gestational age of the fetus matters for counseling.
4. If you are working with a fertility specialist, make sure that clinician knows testosterone was or is on your medication list, even if you have already stopped it.

The prescribing field for compounded testosterone is not tightly regulated, and the absence of an FDA-approved female testosterone product in the United States means there is no mandatory package insert in the patient's hands. Many women are genuinely unaware their prescription carries a contraindication in pregnancy. That is not a failure of the patient. It is a gap in how compounded medications are communicated.

Pregnancy and Lactation Safety: Summary

• Pregnancy: Contraindicated. FDA labeling classifies testosterone as contraindicated in pregnancy due to risk of virilization of female fetuses. Human case report data and animal reproductive toxicology studies both support this classification.
• Lactation: Not recommended. LactMed identifies testosterone as likely to transfer into breast milk and to suppress lactation. Avoid during breastfeeding.
• Contraception requirement: Mandatory for any sexually active woman of reproductive age who remains on low-dose testosterone therapy for any reason.
• If pregnancy occurs on testosterone: Discontinue immediately. Seek OB counseling about timing of fetal exposure and fetal sex, as female fetuses are at highest risk for virilization in the first trimester.

Who This Treatment Is Right For, and Who It Is Not

May Be Appropriate (With Strict Conditions)

• Postmenopausal women with confirmed HSDD who have not responded to non-pharmacological approaches
• Women who are not pregnant, not breastfeeding, not trying to conceive, and are using reliable contraception
• Women managed by a clinician monitoring serum testosterone levels to avoid supraphysiologic dosing

Not Appropriate

• Any woman actively trying to conceive
• Pregnant women, at any trimester
• Breastfeeding women
• Women with PCOS trying to conceive (androgen excess already present)
• Women with androgen-sensitive conditions such as hormone-receptor-positive breast cancer (separate safety concern)
• Premenopausal women without a thorough workup ruling out other causes of low libido